{"entity":{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","aka":[],"tldr":"Off-the-shelf cancer vaccines target antigens shared across patients, such as mutant KRAS or HER2 peptides, so they are made in advance rather than per person. Sipuleucel-T is still the only approved therapeutic cancer vaccine in the US; tolerance to self-antigens and weak past results hold them back.","summary":"KRAS-directed vaccines (ELI-002 7P, Elicio; mRNA-5671), shared neoantigen vaccines (Gritstone SLATE, discontinued), HER2 peptide vaccines, and tumour-lysate approaches. Sipuleucel-T (2010) remains the only approved therapeutic cancer vaccine in the US; BCG for bladder cancer is the oldest immunotherapy.","status":"phase-3","asOf":"2026-09-04","links":[{"label":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers (Clinical Cancer Research 2020)","url":"https://doi.org/10.1158/1078-0432.CCR-19-3517"},{"label":"ClinicalTrials.gov NCT05726864: AMPLIFY-7P","url":"https://clinicaltrials.gov/study/NCT05726864"}],"tags":[],"related":["idea-splice-neoantigens"],"cancers":["pancreatic","colorectal","prostate"],"sections":["immunotherapy"],"technologies":[],"targets":["kras"],"drugs":[],"companies":["gritstone","adventris-pharmaceuticals","curevac","evaxion","guardian-bio","io-biotech","mendus","nykode-therapeutics","ose-immunotherapeutics","tarebio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"A pre-manufactured antigen (peptide, mRNA, viral vector, dendritic cell) is given with an adjuvant.","strengths":["Scalable, immediate"],"limitations":["Tolerance to self-antigens; weak historical results"]},"route":"/technologies/shared-antigen-vaccine/","neighbours":{"idea":[{"id":"idea-moon-lynch-vaccine-phase3","kind":"idea","name":"A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval","route":"/ideas/idea-moon-lynch-vaccine-phase3/"},{"id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/"},{"id":"idea-interception-vaccines","kind":"idea","name":"Cancer interception vaccines for high-risk carriers","route":"/ideas/idea-interception-vaccines/"},{"id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","route":"/ideas/idea-shared-kras-vaccine-adjuvant/"},{"id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/"},{"id":"idea-bio1-resistance-mutation-vaccine","kind":"idea","name":"Vaccinate against the resistance mutation before it takes over","route":"/ideas/idea-bio1-resistance-mutation-vaccine/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","route":"/companies/adventris-pharmaceuticals/"},{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/"},{"id":"curevac","kind":"company","name":"CureVac","route":"/companies/curevac/"},{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/"},{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/"},{"id":"guardian-bio","kind":"company","name":"Guardian Bio","route":"/companies/guardian-bio/"},{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/"},{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/"},{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/"},{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/"},{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/"},{"id":"tarebio","kind":"company","name":"TareBio","route":"/companies/tarebio/"}],"drug":[{"id":"algenpantucel-l","kind":"drug","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/"},{"id":"dcvax-l","kind":"drug","name":"DCVax-L","route":"/drugs/dcvax-l/"},{"id":"eli-002-7p","kind":"drug","name":"ELI-002 7P","route":"/drugs/eli-002-7p/"},{"id":"gi-6301","kind":"drug","name":"GI-6301","route":"/drugs/gi-6301/"},{"id":"prostvac","kind":"drug","name":"PROSTVAC","route":"/drugs/prostvac/"},{"id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/"},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/"}],"trial":[{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/"},{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/"},{"id":"nct00722228","kind":"trial","name":"Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors","route":"/trials/nct00722228/"},{"id":"nct05909423","kind":"trial","name":"Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer","route":"/trials/nct05909423/"},{"id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","route":"/trials/nct06782932/"},{"id":"eclipse","kind":"trial","name":"ECLIPSE (GVAX pancreas and CRS-207)","route":"/trials/eclipse/"},{"id":"impress-trial","kind":"trial","name":"IMPRESS (algenpantucel-L)","route":"/trials/impress-trial/"},{"id":"nct07539155","kind":"trial","name":"Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer","route":"/trials/nct07539155/"},{"id":"nct06134232","kind":"trial","name":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","route":"/trials/nct06134232/"},{"id":"nct05950139","kind":"trial","name":"Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC","route":"/trials/nct05950139/"},{"id":"nct06149481","kind":"trial","name":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can","route":"/trials/nct06149481/"},{"id":"prospect-prostvac","kind":"trial","name":"PROSPECT","route":"/trials/prospect-prostvac/"},{"id":"nct06522919","kind":"trial","name":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mi","route":"/trials/nct06522919/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"},{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/"},{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/"},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"},{"id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/"}],"institution":[{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/"},{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/"},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/"},{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/"},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/"},{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/"},{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/"},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/"},{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/"},{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","route":"/institutions/uva-cancer-center/"}],"technology":[{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/"},{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/"},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/"}],"person":[{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/"},{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/"},{"id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/"},{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/"},{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/"},{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/"},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}],"paper":[{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/"}],"term":[{"id":"vaccines-and-oncolytic-viruses","kind":"term","name":"Cancer vaccines and oncolytic viruses","route":"/terms/vaccines-and-oncolytic-viruses/"}]}}